Duspatal Retard

Quick links

Choose a section

Quick links to important sections

Advertisements

Duspatal Retard

Selected form

Advertisements
Advertisements

Overview of Duspatal Retard

What is Duspatal Retard?

Duspatal Retard is a medication specifically formulated to treat symptoms associated with functional gastrointestinal disorders. It belongs to a group of medicines known as antispasmodics, which work directly on the muscles of the digestive tract.

Composition and Mechanism

The active substance in Duspatal Retard is mebeverine hydrochloride. Unlike some other medications used for digestive issues, mebeverine is a musculotropic antispasmodic. This means it acts directly on the smooth muscle of the gut to relieve spasms and cramps without affecting the normal movement of the intestines. It helps the digestive system return to a relaxed state, alleviating discomfort caused by muscle contractions.

Use Cases

This medication is primarily used to manage symptoms related to Irritable Bowel Syndrome (IBS) and similar conditions. These symptoms often include:

  • Abdominal pain and cramps
  • Persistent diarrhea or alternating constipation
  • Flatulence and bloating
  • Changes in stool consistency

Formulation Characteristics

The "Retard" designation in the name refers to the sustained-release nature of the capsules. The medication is designed to release the active ingredient gradually over an extended period. This delivery method allows for a more consistent concentration of the medicine in the body, typically requiring less frequent administration than standard-release formulations.

Advertisements

What side effects are possible with Duspatal Retard?

Possible Side Effects and Safety Information

The safety profile of Duspatal Retard (mebeverine hydrochloride) is characterized primarily by adverse reactions associated with the immune system and the skin, as documented in official regulatory sources. The majority of reported adverse events are classified as Not Known in terms of frequency, reflecting that their rates of occurrence cannot be reliably estimated from spontaneous post-marketing reports.


Official Adverse Reactions and Classifications

The most frequently reported adverse reactions are manifestations of hypersensitivity and allergic reactions. These effects are grouped within the following System-Organ Classes (SOCs):

System-Organ Class Examples of Documented Reactions
Immune System Disorders Hypersensitivity, Anaphylactic reactions
Skin and Subcutaneous Tissue Disorders Rash, Urticaria (hives), Exanthema, Angioedema

Serious manifestations of allergic reactions officially documented in regulatory information include angioedema (swelling beneath the skin) and facial edema. While these events are rare, their inclusion highlights them as clinically significant adverse reactions. Other less common systemic effects, such as dizziness and headache, have also been reported.


Population-Specific Safety Constraints

Official regulatory documents specify safety limitations regarding certain populations based on available data:

  • Pediatric Population: The medicine is not recommended for use in children and adolescents below 18 years of age, due to insufficient data on efficacy and safety in this group.
  • Pregnancy and Lactation: Use of mebeverine is not recommended during pregnancy or breast-feeding due to a lack of sufficient safety data regarding potential effects on the fetus or infant.

Furthermore, the medicine is contraindicated in individuals with known hypersensitivity to mebeverine hydrochloride or its excipients.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Officially documented information regarding overexposure to Duspatal Retard (mebeverine hydrochloride) indicates that clinical manifestations are typically mild or absent and are usually rapidly reversible. The symptoms reported in overdose situations are characterized as being of a neurological nature and a cardiovascular nature. While observed outcomes are generally non-severe, the potential for CNS excitability is listed as a theoretical manifestation that may occur with substantial overdosage.

If overdosage occurs, regulatory guidance requires that patients talk to a doctor or go to a hospital straight away to seek immediate medical attention. This instruction is essential to facilitate the necessary medical supervision and monitoring of vital functions.

The official regulatory profile confirms that no specific antidote is known for mebeverine. Therefore, management is strictly defined as symptomatic and supportive treatment. Healthcare professionals must monitor the patient’s vital functions closely. Procedural measures, such as gastric lavage, are only considered under specific constraints, such as cases involving multiple intoxication or if the exposure is discovered within one hour. Available post-marketing data has established no specific overdose risk for elderly, renal-impaired, or hepatic-impaired patient populations.

Advertisements

Therapeutic Uses of Duspatal Retard

Quick Facts

  • Therapeutic Domain: Symptomatic management of Irritable Bowel Syndrome (IBS).
  • Relief Focus: Abdominal discomfort, cramping, and pain associated with colon disorders.
  • Symptom Mitigation: Supports the reduction of common IBS symptoms like bloating and irregular bowel function (diarrhea or constipation).

What Duspatal Retard Treats

Duspatal Retard is used for the symptomatic relief of Irritable Bowel Syndrome (IBS). The medication is designed to address functional disturbances of the gut. It helps to ease abdominal pain and alleviate discomfort often reported by individuals with this chronic condition.

Therapeutic use of Duspatal Retard may contribute to the mitigation of associated gastrointestinal symptoms. These symptoms commonly include abdominal cramping, a feeling of bloating, and irregularity in bowel function, such as alternating episodes of diarrhea and constipation. The primary objective of treatment is to provide support for the management of these symptoms, promoting patient comfort and well-being. The treatment is employed for the ongoing management of the condition's manifestations and is directed toward functional bowel disorders.

Regulatory References

  1. EMA therapeutic overview for mebeverine hydrochloride
Advertisements

Eligibility and Restrictions for Use

Official Eligibility Rules for Duspatal Retard

Eligibility for Duspatal Retard (mebeverine hydrochloride modified-release capsules) is strictly defined by population-specific restrictions and contraindications documented in government regulatory sources.

Category Official Regulatory Classification Population Group/Condition
Contraindicated Must Not Use Patients with hypersensitivity to mebeverine hydrochloride or any excipient.
Contraindicated Must Not Use Patients with rare hereditary problems of sugar intolerance (e.g., glucose-galactose malabsorption or sucrose-isomaltase insufficiency).
Standard Use Authorized for Use Adult patients.

Age-Related Eligibility Rules

The medicine is not recommended for use in children and adolescents below 18 years of age due to insufficient data on safety and efficacy for this modified-release formulation. For older adults and those with renal or hepatic impairment, no dosage adjustment is deemed necessary based on available post-marketing data.

Pregnancy and Lactation Eligibility Status

Use is restricted during developmental stages:

  • Pregnancy: Mebeverine is not recommended because there is limited data on its use in pregnant women.
  • Lactation: The medicine should not be used while breastfeeding, as it is unknown whether mebeverine or its metabolites are excreted in human milk.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details only the interaction information explicitly documented in official government regulatory sources, such as the Summary of Product Characteristics (SmPC) and other national prescribing information.

Interaction Scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions None documented. Official regulatory labeling confirms that no dedicated interaction studies have been performed with other medicinal products.
Specific interacting medicines (if explicitly listed) None documented.
Mechanistic basis of interactions Not applicable, as no drug-drug interactions resulting from pharmacokinetic or pharmacodynamic mechanisms are described in the official label.
Timing-based interaction rules None documented. No requirements for separating administration times are specified.
Population-specific interaction notes None documented specifically related to interaction relevance in special populations.
Interaction-related restrictions No formal prohibitions or restrictions involving co-administration with other medications are listed in the official interaction section.

Interaction Classifications (High-Level)

Category Official Regulatory Statement
Interaction severity classification No formal drug-drug interaction classification (e.g., contraindicated, clinically significant) is applicable, due to the regulatory statement concerning the absence of conducted studies.
Regulatory basis Summary of Product Characteristics (SmPC) / EMA-aligned national prescribing information (Section 4.5).
Interaction-context constraints The interaction information is limited to substances tested as part of the regulatory submission, which includes ethanol.

Resulting Interaction Structure

Official interaction statements:

  • The official regulatory documentation explicitly states that no interaction studies have been performed with other medicinal products.
  • The only substance tested for interaction is ethanol (alcohol), and regulatory-submitted studies demonstrated the formal absence of any interaction between mebeverine hydrochloride and ethanol.

Connection to the overall interaction profile: Regulatory documents formally define the product’s interaction structure by emphasizing the current scope of documented findings, which is characterized by the absence of data from dedicated drug-drug interaction studies. Consequently, the label contains no mandated restrictions, timing rules, or exposure-modifying statements for co-administered medicines, aside from the confirmed lack of interaction with alcohol.

Advertisements

Mechanism of Action

Direct Musculotropic Action

Mebeverine, the active component, exerts a direct musculotropic effect on the smooth muscle of the gastrointestinal (GI) tract. This action is distinct from neurogenic mechanisms, as it acts directly on the muscle cell. The mechanism involves the modulation of ion channel permeability within the smooth muscle membrane, which is the primary site of action.


Pathway Modulation

A key intracellular effect is the inhibition of calcium ion ( Ca^2+) influx into the muscle cells.

Limiting the availability of intracellular Ca^2+ directly impacts the contractile apparatus. Furthermore, mebeverine induces a membrane stabilizing effect by modulating the electrical properties of the cell, which raises the threshold for action potential generation in the smooth muscle.


Physiological Consequence

Collectively, these mechanistic cascades result in a reduction of overactive signaling and decreased excitability of the smooth muscle. The mechanism mediates a decrease in the frequency and intensity of contractions, thereby modulating the overall pattern of gastrointestinal motility without abolishing normal gut movement.

Advertisements

Dosage and Administration Information

The usage protocol for the 200 mg modified-release capsule of mebeverine hydrochloride is defined by its specialized formulation, which requires adherence to the oral route of administration. The standard adult dosing regimen requires a fixed dose of one 200 mg capsule taken twice daily—once in the morning and once in the evening—establishing a maximum daily intake of 400 mg.

To ensure the intended effect of the prolonged-release unit, the capsule must be swallowed whole with a sufficient quantity of water (at least 100 ml) and must not be chewed, crushed, or opened. Crushing the capsule compromises the coating intended to govern the gradual, sustained release of the active ingredient, thereby defeating the proper use of the medication. The dose is taken approximately 20 minutes before a meal, linking administration to the digestive cycle.

Treatment duration is flexible and often continues until a satisfactory symptomatic response is achieved, after which a gradual withdrawal may be considered. If a single dose is missed, the forgotten dose should be skipped entirely, and the dosing schedule should be resumed with the next regular dose; a double dose should never be taken to compensate. Dosing remains standardized for many populations, as no specific adjustment is typically required for older adults or individuals with existing renal or hepatic impairment.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Duspatal Retard

Evidence for Symptom Management in Irritable Bowel Syndrome (IBS)

Research explored mebeverine hydrochloride by conducting short-term randomized controlled trials (RCTs) involving participants with IBS. These trials were used in research exploring how symptoms change over defined, short time intervals, typically ranging up to about 16 weeks. Studies explored patient-reported outcomes describing perceived discomfort. Research monitored patterns observed in the studies related to the measured change in the severity and frequency of abdominal pain or cramping. Research also examined measured outcomes related to bowel habits and metrics of daily life, such as quality of life.

Systematic reviews that synthesize the findings of multiple RCTs have been conducted. Evidence suggests that findings were mixed across these trials, particularly regarding the primary endpoint of overall global assessment of all IBS symptoms compared to placebo. Evidence is limited regarding a consistent finding for the primary endpoints across all studies analyzed together.

Research Outcomes Measured in IBS Trials

The main focus of many of the short-term RCTs was the Global Assessment of symptom status. Studies monitored changes in specific outcomes related to the episodic changes of the condition, particularly the intensity and frequency of abdominal pain. Other outcomes related to systemic or functional imbalance that were evaluated included measurements of stool consistency and bowel movement frequency.

Focus on Long-Term Studies and Follow-up

The majority of the available, structured research supporting the evaluation of this medicine was studied for short time intervals. The follow-up durations for many robust studies were limited, commonly running for only 3 to 16 weeks of active monitoring. As a result, long-term effects are not fully established. There is limited information for long-term outcomes, and research provides limited insight into the durability of symptom status or the rate at which symptoms might return (recurrence) over periods extending beyond a few months.

Research Gaps and Uncertainties about Mebeverine

Evidence quality varies across studies, and findings were mixed when many trials were analyzed together for the overall global assessment endpoint. This inconsistency is related to the significant heterogeneity (variability) in how different researchers designed their trials and defined what constitutes a measured change. Comparative evidence is limited regarding research studies that evaluated this medicine against all available newer treatments.

Key Studies & References Assessment Report Mebeverine hydrochloride (Therapeutic overview) - College ter Beoordeling van Geneesmiddelen (CBG)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Duspatal Retard (FAQ)


Q: Can I take Duspatal Retard every day for a long time?

A: Official guidance describes the duration of treatment as flexible, continuing until a satisfactory improvement in symptoms is achieved. When this occurs, official documents note that a gradual withdrawal of the medicine may be considered. The duration of use is determined on a case-by-case basis.


Q: Is it common to feel a little dizzy when starting Duspatal Retard?

A: Dizziness has been reported as an adverse reaction in official safety documents. However, the frequency of this specific effect is classified as 'Not known'. This means the rate at which people experience dizziness cannot be reliably estimated from the data currently available.


Q: Are there certain foods or drinks I should avoid while using it?

A: Regulatory documents explicitly confirm the formal absence of any interaction with ethanol (alcohol). No other specific foods or drinks are formally listed in the official documents as requiring avoidance due to a known interaction.


Q: Does Duspatal Retard interact with common over-the-counter pain relievers?

A: Official regulatory labeling explicitly states that no dedicated interaction studies have been performed with other medicinal products, including common pain relievers. Consequently, the official document contains no mandated restrictions or warnings regarding co-administration.


Q: Are there any reported interactions with herbal supplements?

A: Official regulatory documentation states that no dedicated interaction studies have been performed with other medicinal products. Herbal supplements are not specifically mentioned, and therefore, no formal interaction status is documented.


Q: Can Duspatal Retard affect my ability to drive or operate machinery?

A: The official product information states that the medicine is unlikely to affect the ability to drive or use machines. However, since side effects like dizziness and headache have been reported, official guidance notes that these effects should be considered.


Q: How long does the effect of one dose of Duspatal Retard usually last?

A: The medicine is a modified-release (prolonged-release) formulation designed to release the active ingredient slowly. This design sustains the effect over an extended duration, and this is the basis for its required administration frequency.


Q: Why is the 'Retard' version taken less often than the standard one?

A: The term 'Retard' refers to the medicine's specialized design as a prolonged-release capsule. This formulation controls how slowly the active ingredient is released into the body, allowing the medicine to maintain its effect over a longer period and supports the required administration frequency.


Q: Is it okay to take Duspatal Retard if I have other ongoing medical conditions?

A: Official eligibility rules specify that no dosage adjustment is typically required for people with existing liver or kidney impairment. However, formal contraindications exist for individuals with hypersensitivity or certain rare hereditary sugar intolerances.


Q: Can taking Duspatal Retard cause constipation in some people?

A: The official regulatory documents focus on adverse reactions related to the immune system and skin. Constipation is not formally listed as a documented side effect in the official safety profile.


Q: Is it necessary to take Duspatal Retard exactly before or after a meal?

A: The established protocol for use describes taking the dose approximately 20 minutes before a meal, and it requires the capsule to be swallowed whole with water. This timing relative to the digestive cycle is part of the administration procedure.


Q: What should someone do if they suspect they've taken too much?

A: Official documents describe that seeking advice from a medical professional immediately is necessary in the event of a suspected overdose. Possible symptoms noted in overdose reports include dizziness and increased excitability.


Q: Are there special warnings about Duspatal Retard for people with liver problems?

A: The official regulatory documents state that no specific dosage adjustment is typically required for individuals with existing hepatic (liver) impairment. This is based on available post-marketing data.


Q: Is it possible for Duspatal Retard to make me feel tired or drowsy?

A: The official adverse reaction list does not specifically include 'tiredness' or 'drowsiness' as reported effects. However, dizziness has been reported, which is an effect that should be considered.


Q: Are there reports of Duspatal Retard causing allergic skin reactions?

A: Yes, official safety documents list reactions related to the immune system and the skin. Documented effects include rash, urticaria (hives), exanthema, and angioedema (swelling beneath the skin).


Q: Can I stop taking Duspatal Retard suddenly, or should it be gradual?

A: Official treatment guidance indicates that once a satisfactory symptomatic response is achieved, a gradual withdrawal of the medicine may be considered.


Q: Is Duspatal Retard suitable for people who have lactose intolerance?

A: Official documents list a contraindication for patients with rare hereditary problems of sugar intolerance, such as glucose-galactose malabsorption. Specific excipient ingredients are listed in the official documents for review against any known lactose sensitivity.


Q: Is there a generic version of Duspatal Retard available?

A: The active ingredient in Duspatal Retard is mebeverine hydrochloride. Depending on the country, the drug may be available under different brand names or as an unbranded (generic) version of mebeverine in the modified-release form.


Q: What kind of studies have been done on Duspatal Retard in younger patients?

A: The medicine is not recommended for use in children and adolescents below 18 years of age. This restriction is based on official documentation noting insufficient data on efficacy and safety for this modified-release formulation in that population.


Q: Can Duspatal Retard be taken with antacids or heartburn medicines?

A: Official regulatory documents state that no dedicated interaction studies have been performed with other medicinal products, which applies to antacids and heartburn medicines. Therefore, the official documents contain no mandated restrictions or warnings for co-administration with these products.


Q: Does Duspatal Retard change or affect bowel movements directly?

A: The medicine is a spasmolytic agent, which works by relaxing the smooth muscle of the gut. Its purpose is to control painful muscle spasms and normalize the muscular activity (motility) of the digestive tract. It is not classified as a dedicated anti-diarrheal or laxative.


Q: Can Duspatal Retard be used for stomach cramps not related to IBS?

A: The official indication is for the symptomatic treatment of abdominal pain and cramps in Irritable Bowel Syndrome (IBS). It may also be indicated for similar conditions such as chronic irritable colon and spastic constipation, as documented in regulatory texts.


Q: What is the overall goal of treatment with Duspatal Retard, according to sources?

A: The documented overall goal of treatment is to provide symptomatic relief from abdominal discomfort, pain, and spasms. This is achieved by the medicine's action in stabilizing and normalizing the muscular activity of the digestive tract.


Q: Are there any known interactions between Duspatal Retard and supplements like iron or calcium?

A: Official regulatory documents state that no dedicated interaction studies have been performed with other medicinal products. This lack of testing and formal data applies to mineral supplements like iron or calcium.


Q: Does the official guidance say anything about taking Duspatal Retard with other IBS treatments?

A: Regulatory documents explicitly state that no dedicated interaction studies have been performed with other medicinal products. Because of this, there is no specific official guidance regarding co-administering it with other IBS treatments.


Q: Is Duspatal Retard known to interact with common cold or flu medications?

A: Official regulatory documents state that no dedicated interaction studies have been performed with other medicinal products. This lack of testing applies to common cold or flu medications.


Q: Does Duspatal Retard have a risk of becoming addictive?

A: Authoritative sources typically classify this medicine as non-habit forming or note that it is not associated with dependency. This is consistent with its classification as a musculotropic spasmolytic agent, which acts directly on gut smooth muscle.


Q: Are there any research papers that show how well Duspatal Retard works?

A: Research includes short-term randomized controlled trials (RCTs) that have explored changes in symptoms like abdominal pain/cramping, bowel habits, and quality of life in participants with IBS. The synthesis of study findings, such as in systematic reviews, has documented mixed evidence regarding overall symptom improvement compared to placebo.


Q: Does Duspatal Retard interact with birth control pills?

A: Official regulatory documents state that no dedicated interaction studies have been performed with other medicinal products. This means there is no formal interaction status documented for hormonal contraceptives.


Q: Why do official sources say that Duspatal Retard is 'retard'?

A: The term 'Retard' is used in pharmaceutical naming to indicate that the capsule is a modified-release or prolonged-release formulation. This design ensures the active ingredient is released slowly over an extended period.

Advertisements

How should Duspatal Retard be stored and disposed of?

Official Storage and Disposal Profile

Requirement Type Official Regulatory Statement
Temperature Store below 30 C (or 25 C depending on the formulation). Do not refrigerate or freeze.
Environmental Protection Store in the original package to protect the medicine from moisture and/or light.
Child Safety Keep the capsules out of the reach and sight of children.
Stability Do not use the medicine after the expiry date. If supplied in an HDPE container, discard after three months of opening.
Disposal Do not dispose of this medicine via wastewater or household waste. Return any unused or expired capsules to a pharmacist. Disposal must be in accordance with local requirements, which helps protect the environment.

This profile, derived from authoritative government documents, defines specific constraints necessary for maintaining product integrity. These include mandatory temperature limits and strict prohibitions against cold storage. The regulatory guidance ensures proper handling by requiring storage in the original container for environmental protection and mandates a specific disposal process through a pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Duspatal Retard found in:

A-Z Index: